...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS >HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy
【24h】

HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy

机译：HLA-E变异与在丙型肝炎病毒治疗中被HIV /丙型肝炎病毒合并感染的患者的持续病毒学应答有关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives: To analyze whether human leukocyte antigen (HLA)-E allelic variants are associated with and may predict response to peg-interferon (IFN) alpha and ribavirin treatment in HIV/hepatitis C virus (HCV)-coinfected patients.Design: Retrospective follow-up study.Methods: We studied 321 naive patients who started HCV treatment. HLA-E genotyp-ing was performed by restriction fragment length polymorphism. A sustained virological response (SVR) was defined as undetectable plasma HCV-RNA up through 24 weeks after the end of HCV treatment.Results: The HLA-E*0101 allele increased the odds of achieving SVR for all patients [adjusted odds ratio (aOR) = 2.03 (95% confidence interval, 95% Cl = 1.35-3.06); P=0.001], for HCV genotype (GT) 1/4 patients (aOR = 1.62 (95% Cl = 1.03-2.54), P = 0.035), and for GT2/3 patients [aOR = 9.87 (95% Cl =2.47-31.89), P = 0.001]. For decision tree analysis, the SVR rate increased from 0 to 82.6% and then to 92.5% in GT2/3 patients when the count of HLA-E*0101 alleles increased. In GT1/4 patients with rs809991 7 TT genotype, the SVR rate increased from 33.3 to 54.8% and then to 61.8% when the count of HLA-E0101 alleles increased. In GT1/4 patients with rs8099917 GT/ GG genotype, the SVR rate increased from 15.4 to 22% and then to 44% when the count of HLA-E*0101 alleles increased. The overall percentage of patients correctly classified was 73.2% and the area under the receiver operating characteristic curve (AUROC) was 0.803 ±0.024.Conclusion: The HLA-E*0101 allele was associated with increased odds of HCV clearance and could help to predict SVR among HIV/HCV-coinfected patients on HCV therapy. This would be helpful to avoid treatment in those less likely to respond to pegylated-interferon-alpha and ribavirin treatment.
机译：目的：分析人白细胞抗原（HLA）-E等位基因变体是否与HIV /丙型肝炎病毒（HCV）合并感染的患者的聚乙二醇干扰素（IFN）α和利巴韦林治疗相关联，并可以预测其反应。设计：回顾性研究方法：我们研究了321名开始进行HCV治疗的未治疗患者。通过限制性片段长度多态性进行HLA-E基因分型。持续的病毒学应答（SVR）被定义为在HCV治疗结束后的24周内未检测到血浆HCV-RNA。结果：HLA-E * 0101等位基因增加了所有患者达到SVR的几率[校正比值比（aOR ）= 2.03（95％置信区间，95％Cl = 1.35-3.06）; P = 0.001]，HCV基因型（GT）1/4患者（aOR = 1.62（95％Cl = 1.03-2.54），P = 0.035）和GT2 / 3患者[aOR = 9.87（95％Cl = 2.47） -31.89），P = 0.001]。对于决策树分析，当HLA-E * 0101等位基因计数增加时，GT2 / 3患者的SVR率从0增加到82.6％，然后增加到92.5％。在具有rs809991 7 TT基因型的GT1 / 4患者中，当HLA-E0101等位基因计数增加时，SVR率从33.3增加到54.8％，然后增加到61.8％。在具有rs8099917 GT / GG基因型的GT1 / 4患者中，当HLA-E * 0101等位基因计数增加时，SVR率从15.4％增加到22％，然后增加到44％。正确分类的患者的总百分比为73.2％，接受者操作特征曲线下的面积（AUROC）为0.803±0.024。结论：HLA-E * 0101等位基因与HCV清除几率增加相关，可以帮助预测SVR接受HCV治疗的HIV / HCV合并感染患者中。这将有助于避免那些不太可能对聚乙二醇化干扰素-α和利巴韦林治疗产生反应的患者进行治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号